Disorders of phosphorus, calcium vitamin D are common in patients with renal failure. Medical management, including dietary phosphorus restriction, administration of phosphate binding agents calcium and vitamin D sterol supplementation, must be instituted to control serum concentrations of these substances because of the loss of normal homeostatic mechanisms. If these measures are not employed, soft tissue calcification and hyperparathyroidism may result. We report the case of a 22-year-old woman with endstage renal disease treated with continuous ambulatory peritoneal dialysis who developed secondary hyperparathyroidism and tumorous calcinosis as a result of noncompliance with dietary phosphorus restriction and phosphate-binding agent therapy. The etiology and treatment of soft tissue calcification in patients with renal disease are discussed. Compliance with dietary restrictions and phosphate binding agents is frequently problematic in this population. Pharmacists should play an active role in educating patients with renal disease on the consquences of noncompliance with dietary and drug therapy.
Get full access to this article
View all access options for this article.
References
1.
ParfittAM. Soft-tissue calcification in uremia. Arch Intern Med1969; 124: 544–56.
2.
KuzelaDCHufferWECongerJDWinterSDHammondWS. Soft tissue calcification in chronic dialysis patients. Am J Pathol1977; 86: 403–24.
GambertoglioJGManginiRJRobinsonDC. Kidney diseases. In: KatcherSKYoungLYKoda-KimbleMA, eds. Applied therapeutics: The clinical use of drugs. 3rd ed. Vancouver, WA: Applied Therapeutics, 1985: 539–85.
5.
ContigugliaSRAlfreyACMillerNLRunnelsDELe GerosRZ. Nature of soft tissue calcification in uremia. Kidney Int1973; 4: 229–35.
6.
KatzAIHamperCIMerrillJP. Secondary hyperparathyroidism and renal osteodystrophy in chronic renal failure. Medicine (Baltimore)1969; 48: 333–74.
7.
CangianoJLRamirez-GonzalezRERamirez-MuxoO. Bone disease and soft tissue calcification in chronic peritoneal dialysis. Am J Med Sci1972; 264: 301–6.
8.
De FranciscoAMEllisHAOwenJPParathyroidectomy in chronic renal failure. Q J Med1985; 55: 289–315.
9.
ParfittAMMassrySGWinfieldACDepalmaJRGordonA. Disordered calcium and phosphorus metabolism during maintenance hemodialysis. Am J Med1971; 51: 319–30.
10.
CassidyMJDOwenJPElusHARenal osteodystrophy and metastatic calcification in long-term continuous ambulatory peritoneal dialysis. Q J Med1985; 54: 29–48.
11.
MeemaHEOreopoulosDG. Morphology, progression, and regression of arterial and periarterial calcifications in patients with end-stage renal disease. Radiology1986; 158: 671–7.
12.
SandersCFrankMSRostandSGMetastatic calcification of the heart and lungs in end-stage renal disease: Detection and quantification by dual-energy digital chest radiography. AJR1987; 149: 881–7.
13.
RostandSGSandersCKirkKARutskyEAFraserRG. Myocardial calcification and cardiac dysfunction in chronic renal failure. Am J Med1988; 85: 651–7.
14.
OwenJPParnellAPKeirMJCritical analysis of the use of skeletal surveys in patients with chronic renal failure. Clin Radiol1988; 39: 578–82.
15.
Van Diemen-SteenvoordeRDonckerwolckeRADe HaasG. Generalized soft tissue calcification in children and adolescents with end stage renal failure. Eur J Pediatr1986; 145: 293–6.
16.
AvioliLVTeitelbaumSL. Renal osteodystrophy. In: EarlyLEGottschalkCW. Diseases of the kidney. 3rd ed.Vol. 1. Boston: Little, Brown, 1979: 343–70.
17.
LeeDBGoodmanWGCoburnJW. Renal osteodystrophy: Some new questions on an old disorder. Am J Kidney Dis1988; 11: 365–76.
18.
FeinfeldDASherwoodLM. Parathyroid hormone and 1,25(OH)2D3 in chronic renal failure. Kidney Int1988; 33: 1049–58.
19.
KrogMEierbladSErikssonIJohanssonH. Arterial calcifications in uraemic rats treated with 1-alpha-hydroxycholecalciferol and parathyroidectomy. Scand J Urol Nephrol1984; 18: 227–39.
BrasierARNussbaumSR. Hungry bone syndrome: Clinical and biochemical predictors of its occurrence after parathyroid surgery. Am J Med1988; 84: 654–60.
27.
LlachFFelsenfeldAJColemanMDKeveneyJJPedersonJAMedlockTR. The natural course of dialysis osteomalacia. Kidney Int1986; 29 (S18):S74–9.
28.
SlatopolskyEWeertsCLopez-HilkerSCalcium carbonate as a phosphate binder in patients with renal failure undergoing dialysis. N Engl J Med1986; 315: 157–61.
29.
HerczGKrautJAAndressDAUse of calcium carbonate as a phosphate binder in dialysis patients. Miner Electrolyte Metab1986; 12: 314–9.
30.
EastwoodJBBordierJDe WardenerHE. Some biochemical, histological, radiological and clinical features of renal osteodystrophy. Kidney Int1973; 4: 128–40.
31.
MacTierRAVan StoneJCoxAVan StoneMTwardwoskiZ. Calcium carbonate is an effective phosphate binder when dialysate calcium concentration is adjusted to control hypercalcemia. Clin Nephrol1987; 28: 222–6.
32.
CushnerHMCopleyJBLindbergJSFoulksCJ. Calcium citrate, a nonaluminum-containing phosphate-binding agent for treatment of CRF. Kidney Int1988; 33: 95–9.
33.
MalbertiFSurianMPoggioFMinoiaCSalvadeoA. Efficacy and safety of long-term treatment with calcium carbonate as a phosphate binder. Am J Kidney Dis1988; 12: 487–91.
34.
SheikhMSMaguireJAEmmettMReduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study. J Clin Invest1989; 83: 66–73.
35.
FournierAMorinierePSebertJLCalcium carbonate, an aluminum-free agent for control of hyperphosphatemia, hypocalcemia, and hyperparathyroidism. Kidney Int1986; 29 (S18):S114–9.
36.
SlatopolskyEWeertsCThielanJHorstRHarterHMartinKJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest1984; 74: 2136–43.
37.
DelmezJADouganCSGearingBKThe effects of intraperitoneal calcitriol on calcium and parathyroid hormone. Kidney Int1987; 31: 795–9.
38.
CummingsKMBeckerMHKirschtJPLevinNW. Intervention strategies to improve compliance with medical regimens by ambulatory hemodialysis patients. J Behav Med1981; 4: 111–27.
